StockNews.AI
RLAY
StockNews.AI
181 days

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

1. Relay Therapeutics will report Q4 and full year 2024 results on Feb 26. 2. Company specializes in precision medicine and innovative drug discovery. 3. Focus areas include oncology and genetic diseases using advanced technology.

3m saved
Insight
Article

FAQ

Why Neutral?

While earnings announcements can affect stock prices, Relay's focus remains unchanged.

How important is it?

Earnings reports can influence investor sentiment, though impact may be limited.

Why Short Term?

Near-term impact expected due to upcoming earnings report; hence fluctuations may occur.

Related Companies

VRTXJNJAMGN
February 19, 2025 16:05 ET  | Source: Relay Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter. Contact:Pete Rahmerprahmer@relaytx.com Media:Dan Budwick1AB973-271-6085dan@1abmedia.com

Related News